Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Ishiba Flip-Flops on Copay Cap Hike, Drops Planned Raise in August
Japanese Prime Minister Shigeru Ishiba said on March 7 that his government is canceling its controversial plan to raise the ceiling on patients’ out-of-pocket medical payments in August and lay out a new policy by this fall. This is the…
To read the full story
Related Article
- MHLW to Set Up Special Panel for High-Cost Medical Expense Benefit Program
May 7, 2025
- Japan to Revisit Copay Cap Hike Plan for 2026 and Beyond: Ishiba
March 3, 2025
- Care Avoidance from Copay Cap Hike Likely to Result in 195 Billion Yen Cost Reduction
February 25, 2025
- CDP Submits Bill Calling for Outright Freeze on Copay Cap Reform
February 20, 2025
- Ishiba Vows to Take Steps on OTC-Like Meds from FY2026, Freeze Certain Hikes in Copay Caps
February 19, 2025
- MHLW Proposes Upping Copay Limits in High-Cost Medical Expense Scheme
November 25, 2024
- MHLW Eyes Hiking Copay Cap to Curb Healthcare Spending
November 18, 2024
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…